PEG10
Overview
PEG10 (Paternally Expressed Gene 10) is a paternally imprinted, retrotransposon-derived gene implicated in cell survival and differentiation. In prostate cancer, PEG10 is associated with the neuroendocrine phenotype and has been identified as a transcriptional target of EZH2; its expression is suppressed by EZH2 inhibition, linking it to the epigenetic regulation driving neuroendocrine prostate cancer (CRPC-NE) progression.
Alterations observed in the corpus
- CRPC-NE-associated transcript down-regulated by EZH2 inhibitor GSK343 in NCI-H660 cells; elevated expression in CRPC-NE relative to CRPC-Adeno PMID:26855148
Cancer types (linked)
- CRPC (neuroendocrine subtype): PEG10 expression up-regulated in CRPC-NE and suppressed upon EZH2 inhibition, indicating functional dependence on EZH2-driven epigenetic state PMID:26855148
Co-occurrence and mutual exclusivity
- Co-expressed with NCAM1 (CD56) as a CRPC-NE-associated transcript; both are down-regulated by EZH2 inhibition PMID:26855148
Therapeutic relevance
- EZH2 inhibitor GSK343 down-regulates PEG10 in NCI-H660 (CRPC-NE model), supporting EZH2 as a therapeutic target in CRPC-NE PMID:26855148
Open questions
- Mechanistic role of PEG10 in driving or maintaining the neuroendocrine phenotype vs. being a passenger marker of EZH2 activity has not been established.
Sources
This page was processed by crosslinker on 2026-05-14.